BRPI0512281A - análise dimensional de conjugados de sacarìdeo com gpc & sec-mals - Google Patents

análise dimensional de conjugados de sacarìdeo com gpc & sec-mals

Info

Publication number
BRPI0512281A
BRPI0512281A BRPI0512281-3A BRPI0512281A BRPI0512281A BR PI0512281 A BRPI0512281 A BR PI0512281A BR PI0512281 A BRPI0512281 A BR PI0512281A BR PI0512281 A BRPI0512281 A BR PI0512281A
Authority
BR
Brazil
Prior art keywords
mals
gpc
sec
sample
dimensional analysis
Prior art date
Application number
BRPI0512281-3A
Other languages
English (en)
Inventor
Giorgio Capannoli
Valeria Carinci
Sandro D Ascenzi
Claudia Magagnoli
Original Assignee
Chiron Srl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiron Srl filed Critical Chiron Srl
Publication of BRPI0512281A publication Critical patent/BRPI0512281A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55544—Bacterial toxins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Spectrometry And Color Measurement (AREA)
  • Investigating Or Analysing Materials By Optical Means (AREA)

Abstract

ANáLISE DIMENSIONAL DE CONJUGADOS DE SACARìDEO COM GPC & SEC-MALS. Trata-se de GPC (cromatografia de permeação com gel) e cromatografia de exclusão por dimensionamento com detecção através de fotometria de dispersão de luz por múltiplos ângulos (SEC-MALS), que podem ser usados para medir, com precisão, o tamanho molecular e massa molar, respectivamente, dos conjugados de sacarídeo. A invenção proporciona (a) um processo para medir o tamanho molecular de um antígeno de sacarídeo conjugado dentro de uma amostra, que compreende uma etapa de analisar a amostra através de GPC, e (b) um processo para medir a massa molar de um antígeno de sacarídeo conjugado dentro de uma amostra, que compreende uma etapa de analisar a amostra através de SEC-MALS.
BRPI0512281-3A 2004-06-21 2005-06-21 análise dimensional de conjugados de sacarìdeo com gpc & sec-mals BRPI0512281A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0413868.1A GB0413868D0 (en) 2004-06-21 2004-06-21 Dimensional anlaysis of saccharide conjugates
PCT/IB2005/002532 WO2006000920A2 (en) 2004-06-21 2005-06-21 Dimensional analysis of saccharide conjugates with gpc & sec-mals

Publications (1)

Publication Number Publication Date
BRPI0512281A true BRPI0512281A (pt) 2008-02-26

Family

ID=32750313

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0512281-3A BRPI0512281A (pt) 2004-06-21 2005-06-21 análise dimensional de conjugados de sacarìdeo com gpc & sec-mals

Country Status (13)

Country Link
US (2) US8163296B2 (pt)
EP (2) EP2374473B1 (pt)
JP (5) JP2008503716A (pt)
CN (1) CN1976725B (pt)
AU (1) AU2005256961B2 (pt)
BR (1) BRPI0512281A (pt)
CA (1) CA2571565C (pt)
ES (2) ES2443465T3 (pt)
GB (1) GB0413868D0 (pt)
MX (2) MXPA06015188A (pt)
NZ (1) NZ552449A (pt)
RU (1) RU2422156C2 (pt)
WO (1) WO2006000920A2 (pt)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
GB0413868D0 (en) * 2004-06-21 2004-07-21 Chiron Srl Dimensional anlaysis of saccharide conjugates
PT1896065E (pt) 2005-06-27 2011-08-31 Glaxosmithkline Biolog Sa Processo para a preparação de vacinas
AR064642A1 (es) 2006-12-22 2009-04-15 Wyeth Corp Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
TW201009337A (en) 2008-05-30 2010-03-01 Intervet Int Bv Analytical method to monitor vaccine potency and stability
EP2437882A4 (en) 2009-06-01 2016-11-23 Waters Technologies Corp HYBRID MATERIAL FOR CHROMATOGRAPHY SEPARATIONS
WO2012018596A2 (en) 2010-07-26 2012-02-09 Waters Technologies Corporation Superficially porous materials comprising a substantially nonporous hybrid core having narrow particle size distribution; process for the preparation thereof; and use thereof for chromatographic separations
US8195405B2 (en) * 2009-06-30 2012-06-05 Wyatt Technology Corporation Method for characterizing reversible association of macromolecules at high concentration
MX2012004851A (es) * 2009-10-30 2012-05-22 Novartis Ag Purificacion de sacaridos capsulares de staphylococcus aureus tipo 5 y tipo 8.
EP4023330A1 (en) * 2009-12-15 2022-07-06 Waters Technologies Corporation Device and methods for performing size exclusion chromatography
EP2575773A4 (en) * 2010-05-26 2014-06-25 Selecta Biosciences Inc SYNTHETIC NANOTRÄGERKOMBINATIONSIMPFSTOFFE
AU2011294776B2 (en) 2010-08-23 2016-02-04 Wyeth Llc Stable formulations of Neisseria meningitidis rLP2086 antigens
CA2809758C (en) 2010-09-10 2021-07-13 Wyeth Llc Non-lipidated variants of neisseria meningitidis orf2086 antigens
EP4043029A1 (en) 2012-03-09 2022-08-17 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
US10481164B2 (en) 2012-03-26 2019-11-19 Amgen Inc. Method for using light scattering in real time to directly monitor and control impurity removal in purification processes
ES2685894T3 (es) 2013-03-08 2018-10-15 Pfizer Inc. Polipéptidos de fusión inmunogénicos
MX369534B (es) 2013-09-08 2019-11-11 Pfizer Composiciones de neisseria meningitidis y sus metodos.
RU2723045C2 (ru) 2015-02-19 2020-06-08 Пфайзер Инк. Композиции neisseria meningitidis и способы их получения
EP4309670A3 (en) 2016-09-02 2024-07-17 Sanofi Pasteur, Inc. Neisseria meningitidis vaccine
US11951165B2 (en) 2016-12-30 2024-04-09 Vaxcyte, Inc. Conjugated vaccine carrier proteins
CN118662649A (zh) 2016-12-30 2024-09-20 Vaxcyte公司 具有非天然氨基酸的多肽-抗原缀合物
MX2019009011A (es) 2017-01-31 2019-09-26 Pfizer Composiciones de neisseria meningitidis y metodos respectivos.
CN109459504B (zh) * 2017-09-06 2022-05-27 绿谷(上海)医药科技有限公司 一种测定聚古罗糖醛酸硫酸酯盐重均分子量和含量的方法
CN109459523B (zh) * 2017-09-06 2022-11-08 上海绿谷制药有限公司 一种测定酸性糖可溶性盐重均分子量和含量的方法
JP7409055B2 (ja) * 2019-12-05 2024-01-09 株式会社島津製作所 検出器の出力を補正する方法、および多角度光散乱検出器

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4057685A (en) 1972-02-02 1977-11-08 Abbott Laboratories Chemically modified endotoxin immunizing agent
US4356170A (en) 1981-05-27 1982-10-26 Canadian Patents & Development Ltd. Immunogenic polysaccharide-protein conjugates
US4673574A (en) 1981-08-31 1987-06-16 Anderson Porter W Immunogenic conjugates
US4459286A (en) 1983-01-31 1984-07-10 Merck & Co., Inc. Coupled H. influenzae type B vaccine
US4663160A (en) 1983-03-14 1987-05-05 Miles Laboratories, Inc. Vaccines for gram-negative bacteria
US4761283A (en) 1983-07-05 1988-08-02 The University Of Rochester Immunogenic conjugates
US4808700A (en) 1984-07-09 1989-02-28 Praxis Biologics, Inc. Immunogenic conjugates of non-toxic E. coli LT-B enterotoxin subunit and capsular polymers
JPH01125328A (ja) 1987-07-30 1989-05-17 Centro Natl De Biopreparados 髄膜炎菌ワクチン
NL8802046A (nl) 1988-08-18 1990-03-16 Gen Electric Polymeermengsel met polyester en alkaansulfonaat, daaruit gevormde voorwerpen.
DE3841091A1 (de) 1988-12-07 1990-06-13 Behringwerke Ag Synthetische antigene, verfahren zu ihrer herstellung und ihre verwendung
CA2006700A1 (en) 1989-01-17 1990-07-17 Antonello Pessi Synthetic peptides and their use as universal carriers for the preparation of immunogenic conjugates suitable for the development of synthetic vaccines
WO1991001146A1 (en) 1989-07-14 1991-02-07 Praxis Biologics, Inc. Cytokine and hormone carriers for conjugate vaccines
IT1237764B (it) 1989-11-10 1993-06-17 Eniricerche Spa Peptidi sintetici utili come carriers universali per la preparazione di coniugati immunogenici e loro impiego per lo sviluppo di vaccini sintetici.
SE466259B (sv) 1990-05-31 1992-01-20 Arne Forsgren Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal
ATE128628T1 (de) 1990-08-13 1995-10-15 American Cyanamid Co Faser-hemagglutinin von bordetella pertussis als träger für konjugierten impfstoff.
US5153312A (en) 1990-09-28 1992-10-06 American Cyanamid Company Oligosaccharide conjugate vaccines
IT1262896B (it) 1992-03-06 1996-07-22 Composti coniugati formati da proteine heat shock (hsp) e oligo-poli- saccaridi, loro uso per la produzione di vaccini.
IL102687A (en) 1992-07-30 1997-06-10 Yeda Res & Dev Conjugates of poorly immunogenic antigens and synthetic pepide carriers and vaccines comprising them
ATE400295T1 (de) 1995-06-07 2008-07-15 Glaxosmithkline Biolog Sa Vakzine mit einem polysaccharide antigen- trägerprotein konjugat und freiem trägerprotein
US6299881B1 (en) 1997-03-24 2001-10-09 Henry M. Jackson Foundation For The Advancement Of Military Medicine Uronium salts for activating hydroxyls, carboxyls, and polysaccharides, and conjugate vaccines, immunogens, and other useful immunological reagents produced using uronium salts
GB9713156D0 (en) 1997-06-20 1997-08-27 Microbiological Res Authority Vaccines
US7018637B2 (en) 1998-02-23 2006-03-28 Aventis Pasteur, Inc Multi-oligosaccharide glycoconjugate bacterial meningitis vaccines
DE69941574D1 (de) 1998-08-19 2009-12-03 Baxter Healthcare Sa Immunogenes beta-propionamido-gebundenes polysaccharid-protein konjugat geeignet als impfstoff und hergestellt bei verwendung von n-acryloyliertem polysaccharid
HU228499B1 (en) 1999-03-19 2013-03-28 Smithkline Beecham Biolog Streptococcus vaccine
AU781027B2 (en) 1999-04-09 2005-04-28 Department Of Health & Human Services Recombinant toxin a protein carrier for polysaccharide conjugate vaccines
DK1897555T3 (da) 2000-01-17 2014-10-13 Novartis Vaccines & Diagnostic Kompletteret OMV-vaccine mod meningococcus
GB0007432D0 (en) 2000-03-27 2000-05-17 Microbiological Res Authority Proteins for use as carriers in conjugate vaccines
US6936261B2 (en) 2000-07-27 2005-08-30 Children's Hospital & Research Center At Oakland Vaccines for broad spectrum protection against diseases caused by Neisseria meningitidis
GB0103170D0 (en) 2001-02-08 2001-03-28 Smithkline Beecham Biolog Vaccine composition
HU230490B1 (hu) * 2001-01-23 2016-08-29 Sanofi Pasteur Inc. Multivalens, meningokokkusz-eredetű poliszaccharid és fehérje konjugátumát tartalmazó vakcina
AU2002309706A1 (en) * 2001-05-11 2002-11-25 Aventis Pasteur, Inc. Novel meningitis conjugate vaccine
GB0115176D0 (en) * 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
HUE031886T2 (en) * 2002-10-11 2017-08-28 Glaxosmithkline Biologicals Sa Polypeptide vaccines for extensive protection against hypervirulent meningococcal lines
CA2514328C (en) 2003-01-30 2020-01-14 Chiron Srl Injectable vaccines against multiple meningococcal serogroups
GB0323103D0 (en) 2003-10-02 2003-11-05 Chiron Srl De-acetylated saccharides
EP1670506B1 (en) * 2003-10-02 2012-11-21 Novartis AG Liquid vaccines for multiple meningococcal serogroups
GB0408978D0 (en) 2004-04-22 2004-05-26 Chiron Srl Meningococcal fermentation for preparing conjugate vaccines
GB0413868D0 (en) * 2004-06-21 2004-07-21 Chiron Srl Dimensional anlaysis of saccharide conjugates

Also Published As

Publication number Publication date
AU2005256961B2 (en) 2011-06-23
US8163296B2 (en) 2012-04-24
GB0413868D0 (en) 2004-07-21
US20080248059A1 (en) 2008-10-09
JP2017134084A (ja) 2017-08-03
JP2008503716A (ja) 2008-02-07
JP2014111654A (ja) 2014-06-19
JP6218327B2 (ja) 2017-10-25
CA2571565A1 (en) 2006-01-05
MXPA06015188A (es) 2007-03-27
EP2374473B1 (en) 2018-07-18
MX344621B (es) 2017-01-03
US20120207781A1 (en) 2012-08-16
NZ552449A (en) 2010-05-28
CN1976725B (zh) 2012-08-29
JP2011246490A (ja) 2011-12-08
EP2374473A1 (en) 2011-10-12
RU2007102016A (ru) 2008-07-27
JP2015180707A (ja) 2015-10-15
CN1976725A (zh) 2007-06-06
AU2005256961A1 (en) 2006-01-05
CA2571565C (en) 2014-08-12
WO2006000920A3 (en) 2006-03-30
WO2006000920A2 (en) 2006-01-05
ES2443465T3 (es) 2014-02-19
EP1778291B1 (en) 2013-10-30
RU2422156C2 (ru) 2011-06-27
ES2688796T3 (es) 2018-11-07
EP1778291A2 (en) 2007-05-02
JP6661568B2 (ja) 2020-03-11

Similar Documents

Publication Publication Date Title
BRPI0512281A (pt) análise dimensional de conjugados de sacarìdeo com gpc & sec-mals
WO2007090147A3 (en) Method and apparatus for measurement of optical properties in tissue
DE602004028445D1 (de) Lichtdurchlässige festmatrix-prüfvorrichtung zur mikroarray-analyse
BRPI0509068A (pt) métodos para determinar quantitativamente heparinas de constituição especìfica ou heparinas de baixo peso molecular usando hplc
AR054474A1 (es) Formulacion de anticuerpos estables
AR031557A1 (es) Sonda optica y metodos para analisis espectral.
SE0800724L (sv) Blodviskositetsanalys
BR112015001509A2 (pt) método para determinar uma característica de uma amostra
WO2007090378A3 (de) Messvorrichtung zur bestimmung der grösse, grössenverteilung und menge von partikeln im nanoskopischen bereich
BR112018016018A2 (pt) sensor e dispositivo para aplicações de imagem e de deteção do tempo de vida útil
EP1359417A3 (en) Devices and methods for analyte concentration determination
BRPI0008719B8 (pt) Método para radiomarcação de um anticorpo conjugado a um quelante com 90y e ensaio de ligação para determinação da ligação percentual de um anticorpo radiomarcado à sua célula alvo
WO2006138294A3 (en) Fiber-optic assay apparatus based on phase-shift interferometry
DE60326336D1 (de) Vorrichtung und verfahren um gleichzeitig verschiedene antikörper und antigene nachzuweisen in klinischen, nahrungsmittel- und umwelt-proben
CN106841118A (zh) 光谱测量系统及测量方法
BR112015001310A2 (pt) analisador de característica portátil
ATE551055T1 (de) Nachweis von succinylaceton
BR112018067435A2 (pt) kit de espectrometria de massa
CA2701341A1 (en) Method of assessing colorectal cancer from a stool sample by use of the marker combination calprotectin and hemoglobin/haptoglobin complex
NO20023811L (no) Sammensetninger og fremgangsmåter for overflatepreging
CY1112090T1 (el) Μεθοδος για ανιχνευση βιολογικων οργανισμων με χρηση σκεδασης raman
TW200643367A (en) An apparatus and method for improving the measuring accuracy in the determination of structural data
ATE528635T1 (de) Partikelkonzentrations-messvorrichtung und messverfahren
WO2005040759A3 (en) Apparatus and methods for detecting target analyte
WO2007126882A3 (en) Analysis of splice variant expression data

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B15K Others concerning applications: alteration of classification

Ipc: A61K 39/095 (2006.01), A61K 47/64 (2017.01), A61K

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B25D Requested change of name of applicant approved

Owner name: NOVARTIS VACCINES AND DIAGNOSTICS SRL (IT)

B25D Requested change of name of applicant approved

Owner name: NOVARTIS VACCINES AND DIAGNOSTICS SRL (IT)

B25L Entry of change of name and/or headquarter and transfer of application, patent and certificate of addition of invention: publication cancelled

Owner name: NOVARTIS VACCINES AND DIAGNOSTICS SRL (IT)

Free format text: ANULADA A PUBLICACAO CODIGO 25.4 NA RPI NO 2547 DE 29/10/2019 POR NAO TER SIDO DISPONIBILIZADO O PARECER.

B25A Requested transfer of rights approved

Owner name: NOVARTIS PHARMA AG (CH)

B25A Requested transfer of rights approved

Owner name: NOVARTIS AG (CH)

B25A Requested transfer of rights approved

Owner name: GLAXOSMITHKLINE BIOLOGICALS S.A. (BE)

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]